Genomic profiling of non-small cell lung cancer with the rare pulmonary lymphangitic carcinomatosis and clinical outcome of the exploratory anlotinib treatment

Genomic profiling of non-small cell lung cancer with the rare pulmonary lymphangitic carcinomatosis and clinical outcome of the exploratory anlotinib treatment

BackgroundTo evaluate the potential treatment for patients with non-small cell lung cancer (NSCLC) and rare malignant pulmonary lymphangitis carcinomatosis (PLC), our study provided a genomic profile and clinical outcome of this group of patients.MethodsWe retrospectively reviewed patients with NSCL...

Full description

Bibliographic Details
Main Authors: Changqing Dong, Wanwan Cheng, Meiling Zhang, Si Li, Lele Zhao, Dongsheng Chen, Yong Qin, Mingzhe Xiao, Shencun Fang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Oncology
Subjects:
pulmonary lymphangitic carcinomatosis (PLC)
non-small cell lung cancer (NSCLC)
genomic profiling
anlotinib
survival
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.992596/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.992596/full

Similar Items